Quest Diagnostics Inc DGX

Revenue Intelligence Report • 70 quarters of SEC filing data • Updated 2026-03-06

Quest Diagnostics Inc. has demonstrated a robust revenue generation capability, with its latest quarterly revenue reaching $2,806 million. However, the company's SG&A spending has a negative long-run impact on revenue, with each dollar spent resulting in a decrease of $37.40, indicating a need for more efficient cost management. Despite a projected FY revenue of $11 billion, reflecting a 2.7% year-over-year decline, the company's accurate forecasting model, with a 1.5% error margin, suggests it can navigate market challenges effectively. Investors should monitor the company's strategic initiatives to enhance ROI and stabilize revenue growth moving forward.

Next FY Revenue

$10.74B

-2.7% YoY

SG&A Multiplier

$-37.40 per $1

Model Accuracy

2.9% MAPE

Holdout validation: The model predicted $3B vs the actual $3B — an error of 1.5%.

⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Note: Quest Diagnostics Inc does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$3B	$3B	$3B – $3B	+5.5%	✓ In range
Q2 2026	$3B		$2B – $3B	+2.3%
Q3 2026	$3B		$2B – $3B	-2.3%
Q4 2026	$3B		$2B – $3B	-4.7%
Q1 2027	$3B		$2B – $3B	-5.6%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch